Beijing concedes that Chinese vaccines ‘do not have very high protection rates’

BEIJING (AP) – In a rare acknowledgment of the weakness of Chinese coronavirus vaccines, the country’s leading disease control officer says its effectiveness is low and that the government is considering mixing it to give them a boost.

Chinese vaccines “do not have very high protection rates,” China Centers for Disease Control director Gao Fu said at a conference in the southwestern city of Chengdu on Saturday.

Beijing has distributed hundreds of millions of doses in other countries while also trying to question the effectiveness of Western vaccines.

Get The Times of Israel Daily Edition by Email and Never Miss Our Top Stories Free Sign Up

“It is now formally being considered whether we should use different vaccinations from different technical lines for the vaccination process,” Gao said.

The researchers in Brazil found that the effectiveness rate of a coronavirus vaccine from Sinovac, a Chinese developer, for the prevention of symptomatic infections is up to 50.4%. For comparison, the vaccine made by Pfizer was found to be 97% effective.

Beijing has yet to approve foreign vaccines for use in China, where the coronavirus originated in late 2019.

Illustrative: A worker inspects bottles of SARS CoV-2 vaccine for COVID-19 manufactured by SinoVac at its Beijing factory on Thursday, September 24, 2020 (AP Photo / Ng Han Guan)

Gao gives no details on possible changes in strategy, but mentions mRNA, a previously experimental technique used by Western vaccine developers, while China’s drug manufacturers use traditional technology.

“Everyone should consider the benefits that mRNA vaccines can bring to humanity,” Gao said. “We have to follow it closely and not ignore it, because we already have different types of vaccines.”

Gao had earlier raised questions about the safety of mRNA vaccines. He told the official Xinhua News Agency in December that he could not rule out negative side effects as they were being used on healthy people for the first time.

Chinese state media and popular health and science blogs also question the safety and efficacy of the Pfizer vaccine, which uses mRNA.

As of April 2, about 34 million people had both received the two doses needed by Chinese vaccines, and about 65 million, according to Gao, said.

Experts believe that the mixing of vaccines, or sequential vaccination, can increase the effectiveness rates. Trials around the world are looking at mixing vaccines or increasing the shot after a longer period of time. Researchers in Britain are studying a possible combination of Pfizer and AstraZeneca vaccines.

I’m proud to work for The Times of Israel

I will tell you the truth: life here in Israel is not always easy. But it is full of beauty and meaning.

I am proud to work with The Times of Israel with colleagues who pour out their hearts in their work day by day to capture the complexity of this extraordinary place.

I believe that our reporting provides an important tone of honesty and decency that is essential to understanding what is really happening in Israel. It takes a lot of time, dedication and hard work from our team to get it right.

Your support through membership of The Times of Israel Community, enables us to continue our work. Would you join our community today?

Thank you,

Sarah Tuttle Singer, New Media Editor

Join the Times of Israel community Join our community Already a member? Sign in to stop seeing it

You’re serious. We appreciate it!

That’s why we come to work every day – to give critical readers like you a mandatory coverage of Israel and the Jewish world.

So now we have a request. Unlike other newspapers, we have not yet put up a paywall. But because the journalism we do is expensive, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.

For as little as $ 6 a month, you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as access to exclusive content available only to members of the Times of Israel community.

Join our community Join our community Already a member? Sign in to stop seeing it

Source